Clinical Trial Update: A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) [Phase 3]

View source ↗

Summary

Phase 3 trial investigating camrelizumab plus chemotherapy with or without famitinib as neoadjuvant therapy for triple-negative breast cancer is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chemotherapy (chemotherapy)
• Famitinib (Famitinib)

Snippet

Sponsor: Fudan University | Conditions: TNBC - Triple-Negative Breast Cancer | Phase 3 | Status: RECRUITING